Piramal Pharma (PPLPHARMA) Fundamentals 2026 — Revenue Analysis | SniperIQ
Piramal Pharma (PPLPHARMA) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹23,514 Crore, trading at ₹177.05 on the BSE. This SniperIQ fundamentals page covers Piramal Pharma's valuation, profitability (net margin -3.7%), revenue (₹8,869 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Piramal Pharma's market cap?
Piramal Pharma (PPLPHARMA) has a market capitalization of approximately ₹23,514 Crore, trading at ₹177.05 on the BSE. Market cap moves with the live share price.
What is Piramal Pharma's P/E ratio?
Piramal Pharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Piramal Pharma?
Piramal Pharma runs a net profit margin of -3.7%, a gross margin of 45.2%, and an operating margin of 1.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Piramal Pharma generate?
Piramal Pharma reported revenue of ₹8,869 Crore for fiscal year 2026, with net income of -₹326 Crore and earnings per share (EPS) of -2.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Piramal Pharma pay a dividend?
Piramal Pharma offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Piramal Pharma financially healthy?
Piramal Pharma carries a debt-to-equity ratio of 0.70x and a current ratio of 1.51x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Piramal Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Piramal Pharma (PPLPHARMA) the key facts are: market cap ₹23,514 Crore, revenue ₹8,869 Crore, 52-week range 132.5-210.35. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Piramal Pharma's full fundamentals live
Get Piramal Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.